Evaluation of efficacy of erlotinib in patients with untreated, EGFR mutation positive, untreated-locally advanced NSCLC.
Not Applicable
- Conditions
- ntreated, EGFR mutation positive, untreated-locally advanced NSCLC.
- Registration Number
- JPRN-UMIN000011467
- Lead Sponsor
- agasaki Thoracic Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1)Having interstitial pneumonitis 2)Uncontrolable complications
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method surgical resectability
- Secondary Outcome Measures
Name Time Method